for the Period Ended 31 December 2025
| Balance sheet | |
| Notes |
As at
|
Notes |
2025 |
2024 |
|
|---|---|---|---|
|
|
£ |
£ |
|
| Called up share capital not paid: |
|
|
|
| Fixed assets | |||
| Investments: | 3 |
|
|
| Total fixed assets: |
|
|
|
| Current assets | |||
| Creditors: amounts falling due within one year: | 4 |
( |
( |
| Net current assets (liabilities): |
( |
( |
|
| Total assets less current liabilities: |
|
|
|
| Total net assets (liabilities): |
|
|
|
| Capital and reserves | |||
| Called up share capital: |
|
|
|
| Other reserves: |
|
|
|
| Profit and loss account: |
( |
( |
|
| Shareholders funds: |
|
|
The notes form part of these financial statements
The directors have chosen to not file a copy of the company’s profit & loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 December 2025
for the Period Ended 31 December 2025
| 2025 | 2024 | |
|---|---|---|
| Average number of employees during the period |
|
|
for the Period Ended 31 December 2025
Investments Subsidiaries Cost or valuation At 1 January 2024 £4,719,967 At 31 December 2024 £4,719,967 At 31 December 2025 £4,719,967 Impairment At 1 January 2024 Nil At 31 December 2024 Nil Additions £1,163,728 At 31 December 2025 £1,163,728 Net book value At 1 January 2024 £4,719,967 At 31 December 2024 £4,719,967 At 31 December 2025 £3,556,239 During the year, the Company recognised an impairment charge of £1,163,728 (2024: £Nil) in respect of its investment in subsidiary undertakings following management’s impairment review performed at year end.
for the Period Ended 31 December 2025
for the Period Ended 31 December 2025
for the Period Ended 31 December 2025